UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

 UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

Shots:

  • The P-IIb study involves assessing of bimekizumab (160/320 mg@ 48 wks./16mg @12wks., q4w SC IV) vs PBO in 206 patients in ratio (1:1) with PsA
  • P-IIb BE ACTIVE study results: @12wks. ACR20/50/70/ (20%, 50% vs 7%,70%): PASI90/95 (90%,75%); @ 48wks. ACR20/50/70 (160, loading dose 160, 320): (70%, 73%, 76%; 55%, 57%, 63%; 43%, 46%, 39%); PASI90 (70%, 85%); MDA @12/24/48 wks. ((29-46%), (37-60%), (46-60%))
  • Bimekizumab is a novel mIgG1 Ab neutralizes IL-17A and IL-17F. The above mentioned results are presented at ACR/ARHP18

Click here to read full press release/ article | Ref: UCB | Image: Eatris

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post